https://pubmed.ncbi.nlm.nih.gov/38113873

The number of neoadjuvant chemotherapy cycles in advanced epithelial ovarian cancer does not significantly affect disease-free or overall survival, with the key factor in survival being the absence of macroscopic residual tumor tissue after interval cytoreductive surgery.